FDA accepts uniQure’s Huntington’s gene therapy for priority review—but the evidence remains unsettled

The story

The US Food and Drug Administration has accepted uniQure’s application for ifezuntirgene inilparvovec, an experimental gene therapy for Huntington’s disease, and granted it priority review. The company disclosed a May 1, 2027 target date for an agency decision and said the FDA is tentatively planning an advisory committee meeting. Acceptance starts a formal review; it does not mean the therapy has been found safe, effective or approvable.

The candidate, previously known as AMT-130, is designed as a one-time treatment. An adeno-associated virus type 5 vector carries an engineered microRNA intended to reduce production of huntingtin, including the toxic exon 1 protein fragment associated with the inherited neurodegenerative disorder. Delivery is unusually intensive: surgeons use MRI-guided, convection-enhanced infusion to place the vector directly into the caudate and putamen, structures within the brain’s striatum.

The potential benefit is substantial because no approved treatment has been shown to slow Huntington’s disease progression. Existing care can address movement, psychiatric and other symptoms but cannot stop the underlying decline. UniQure says approval would make ifezuntirgene inilparvovec the first disease-modifying treatment. That claim remains conditional on the FDA accepting both the evidence and the proposed balance between benefit, neurosurgical risk and long-term gene-therapy uncertainty.

The evidence package is also unconventional. UniQure’s application is anchored in Phase I/II studies and a 36-month analysis that compared treated participants with propensity-matched patients from the Enroll-HD natural-history database, rather than a contemporaneous randomized control group. Reuters reports that 51 people have received the therapy across the studies, but the regulatory comparison is based on smaller subsets with sufficient follow-up. External controls can be useful in rare diseases, yet differences in patient selection, follow-up and missing data can create bias that randomization is meant to reduce.

Longer follow-up sharpened that problem. In September, uniQure reported that 12 high-dose patients showed 44% slower decline than the updated external control on the composite Unified Huntington’s Disease Rating Scale at 48 months. The primary comparison did not reach statistical significance, with a nominal p-value of 0.144. Total Functional Capacity, a secondary measure of daily independence, showed a 61% slowing with a nominal p-value of 0.008. UniQure argued that extensive missing data made the external comparison increasingly unfavorable; that explanation is plausible but not a substitute for a randomized result.

The agency’s position has already changed. Company filings show that in March 2026 the FDA would not agree that the Phase I/II data and external control supplied sufficient primary evidence for a marketing application and strongly recommended a prospective, randomized, double-blind, sham-surgery-controlled study. The regulator later allowed the accelerated-approval submission. Reuters reports that a senior FDA official had called AMT-130 a “failed product” during the dispute, underscoring how contested the evidentiary path has been.

Priority review should not be mistaken for relaxed review. FDA guidance says the designation sets a goal of acting within six months but does not change the scientific or medical standard for approval. The accelerated-approval pathway can rely on a surrogate or intermediate endpoint considered reasonably likely to predict clinical benefit, with a later trial required to verify that benefit. If confirmation fails, the agency can withdraw an accelerated approval.

UniQure and the FDA have aligned on the outline of that confirmatory study. About 200 participants would be assigned two-to-one to the gene therapy or standard care, with Total Functional Capacity at 36 months as the primary endpoint. US screening is planned to begin before the end of 2026. The absence of a sham-surgery control avoids exposing untreated participants to brain surgery, but it may complicate blinding and interpretation of a procedure-intensive intervention.

INNOVOX analysis: this review will test how much uncertainty accelerated approval can carry in a progressive genetic brain disease with no disease-modifying therapy. The mechanism is technically coherent and early signals are important, yet the small cohorts, external comparator and weakened four-year primary result leave a genuine evidence gap. The May decision will matter, but the decisive scientific question is longer-term: whether a randomized trial reproduces a clinically meaningful preservation of independence without unacceptable surgical or biological risk.

INNOVOX analysis

The regulatory question is larger than whether an innovative vector can lower huntingtin. It is whether a small, surgically treated cohort compared with non-randomized historical patients can reliably predict durable functional benefit. A positive decision could open a route for rare neurodegenerative gene therapies, but it would also make the confirmatory trial and post-approval enforcement unusually important.

What to watch

Watch whether the FDA convenes the tentatively planned advisory committee, which data cut it treats as decisive, and how reviewers handle missing external-control data at 48 months. The design, launch and enrollment pace of the randomized 200-patient confirmatory trial will be as important as the May 2027 decision itself.